Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).
暂无分享,去创建一个
A. Krishnan | J. Goldberg | A. Oriol | J. Russell | R. Verona | E. Askari | A. Chari | B. Hilder | M. Minnema | M. Mateos | L. Costa | T. Prior | J. Berdeja | N. V. D. Donk | S. Girgis | P. Rodríguez-Otero